US Patent Issued to EG BIOMED, EG BIOMED AU on March 25 for "Methods for early prediction, treatment response, recurrence and prognosis monitoring of pancreatic cancer" (Taiwanese Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,636, issued on March 25, was assigned to EG BIOMED Co. LTD. (Taipei, Taiwan) and EG BIOMED AU PTY LTD (Melbourne, Australia).

"Methods for early prediction, treatment response, recurrence and prognosis monitoring of pancreatic cancer" was invented by Ruo-Kai Lin (Taipei, Taiwan) and Hsieh-Tsung Shen (Taipei, Taiwan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention discloses a set of novel epigenetic biomarkers for early prediction, treatment response, recurrence and prognosis monitoring of pancreatic cancer. Aberrant methylation of genes can be detected in tumor tissues and plasma samples from pancreatic cancer patients but not i...